Open AccessP1102: A PHASE 1 STUDY OF PARSACLISIB IN COMBINATION WITH RITUXIMAB, BENDAMUSTINE + RITUXIMAB, OR IBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL LYMPHOMA (CITADEL‐112): PRELIMINARY SAFETY RESULTS
Author(s) -
Sancho J.M.,
LopezGuillermo A.,
Abrisqueta P.,
Kumar A.,
Cordoba R.,
Tani M.,
Zhao W.,
Rappold E.,
Langmuir P.,
Mims M.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000847276.06711.b7
Subject(s) - bendamustine , ibrutinib , medicine , rituximab , idelalisib , mantle cell lymphoma , tolerability , chemoimmunotherapy , lenalidomide , bruton's tyrosine kinase , follicular lymphoma , oncology , lymphoma , gastroenterology , adverse effect , leukemia , chronic lymphocytic leukemia , tyrosine kinase , multiple myeloma , receptor